MannKind Corporation (NASDAQ:MNKD) traded 11.31% higher to close last trading session at $4.43 as its first-quarter loss of $41 million or 15 cents per share declined from a loss of $38.2 million or 27 cents per share, in the same quarter of 2012 and matched the average prediction of analysts surveyed by FactSet. The stock’s year-to-date performance now stands around +91.77%.

http://www.therem.org/best-5-worst-5-biotech-stocks-sequenom-theravance-mannkind-alexion-illumina-pain-therapeutics-affymax-optimer-anacor-discovery-laboratories/123936/